Compare CHE & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | TFX |
|---|---|---|
| Founded | 1970 | 1943 |
| Country | United States | United States |
| Employees | 15695 | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 1994 | 1994 |
| Metric | CHE | TFX |
|---|---|---|
| Price | $408.64 | $114.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $498.00 | $140.25 |
| AVG Volume (30 Days) | 225.1K | ★ 907.5K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | 0.59% | ★ 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 18.34 | N/A |
| Revenue | ★ $2,529,978,000.00 | $1,992,713,000.00 |
| Revenue This Year | $6.60 | $85.12 |
| Revenue Next Year | $6.15 | $4.47 |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $385.00 | $100.18 |
| 52 Week High | $623.61 | $143.32 |
| Indicator | CHE | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 50.89 |
| Support Level | $385.00 | $109.60 |
| Resistance Level | $462.68 | $125.89 |
| Average True Range (ATR) | 13.68 | 5.10 |
| MACD | -6.26 | 0.54 |
| Stochastic Oscillator | 24.18 | 51.38 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.